Early onset familial Alzheimer's disease
Not recruitingStudy on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer's Disease
Study on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer's Disease
- Disease:Early onset familial Alzheimer's disease
- Substances:Florquinitau (18F)Humanised Igg1 Monoclonal Antibody Against N-Terminally Truncated Pyroglutamate-3 Ab
Italy- Participants:18–64 years · 65+ years
- Substances:Florquinitau (18F)
- Sponsor:AbbVie Deutschland GmbH & Co. KG













